Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study

被引:93
|
作者
Zakai, N. A.
Katz, R.
Jenny, N. S.
Psaty, B. M.
Reiner, A. P.
Schwartz, S. M.
Cushman, M.
机构
[1] Brown Univ, Dept Med, Providence, RI 02912 USA
[2] Boston Univ, Providence, RI USA
[3] Univ Washington, Dept Biostat, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA
[4] Univ Vermont, Dept Pathol, Coll Med, Burlington, VT USA
[5] Univ Washington, Sch Med,Dept Med, Cardiovasc Hlth Res Unit, Div Gen Internal Med, Seattle, WA 98195 USA
[6] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[7] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA
关键词
aging; cardiovascular disease; cohort studies; epidemiology; inflammation; risk factors;
D O I
10.1111/j.1538-7836.2007.02528.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There are few studies of inflammation and hemostasis biomarkers and cardiovascular disease risk (CVD) in older adults. Objectives: To assess multiple biomarkers simultaneously and in combinations for CVD risk assessment in older individuals. Patients/methods: Thirteen biomarkers, interleukin-6 (IL-6), C-reactive protein (CRP), D-dimer, fibrinogen, factor VII, factor VIII, leukocyte count (WBC), platelet count, lipoprotein(a), soluble intercellular adhesion molecule-1 (sICAM-1), albumin, homocysteine and uric acid, were correlated with incident CVD in 4510 individuals in the Cardiovascular Health Study. Baseline biomarkers were analyzed as gender-specific SD increments and quintiles in proportional hazards models adjusted for demographics, CVD risk factors and medications. Results: Over 9 years with 1700 CVD events, seven biomarkers were associated with CVD. Adjusted hazard ratios (HRs, 95% CI) per SD increment were 1.16 (1.09, 1.23) for IL-6, 1.16 (1.09, 1.23) for CRP, 1.13 (1.05, 1.21) for D-dimer, 1.17 (1.09, 1.25) for homocysteine, 1.06 (1.00, 1.12) for WBC, 1.06 (1.00, 1.12) for factor VIII, and 1.07 (1.00, 1.13) for lipoprotein(a). Fibrinogen was associated with CVD in men only (HR 1.12, 95% CI 1.04, 1.22) and sICAM-1 in women only (HR 1.16, 95% CI 1.05, 1.27). IL-6 and CRP remained associated with CVD when modeled with WBC. Participants were classified by all combinations of two biomarkers being high or low (IL-6, CRP, WBC, factor VIII, cholesterol/HDL). All were associated with CVD when cholesterol/HDL was low and none when CRP was low. Conclusions: Seven biomarkers were associated with CVD in older adults, with CRP having some advantages compared with others. Even larger studies are needed to better characterize these associations.
引用
收藏
页码:1128 / 1135
页数:8
相关论文
共 50 条
  • [31] Increased cardiovascular mortality in exhausted and physically weak elderly: The cardiovascular health study
    Kop, WJ
    Fried, LP
    McBurnie, M
    Tangen, C
    Walston, J
    Hirsch, C
    Tracy, RP
    Newman, A
    Schulz, R
    Gottdiener, JS
    CIRCULATION, 1998, 98 (17) : 583 - 583
  • [32] Biomarkers for cardiovascular risk in children
    Canas, Jose A.
    Sweeten, Shawn
    Balagopal, Prabhakaran
    CURRENT OPINION IN CARDIOLOGY, 2013, 28 (02) : 103 - 114
  • [33] Multiple biomarkers and cardiovascular risk
    Austin, Mark J.
    Heneghan, Michael A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (07): : 760 - 761
  • [34] Novel biomarkers for cardiovascular risk
    Serra, Raffaele
    Ielapi, Nicola
    Barbetta, Andrea
    Andreucci, Michele
    de Franciscis, Stefano
    BIOMARKERS IN MEDICINE, 2018, 12 (09) : 1015 - 1024
  • [36] Hemoglobin Decline and Health Outcomes in the Elderly: the Cardiovascular Health Study
    Zakai, Neil A.
    French, Benjamin
    Arnold, Alice
    Newman, Anne
    Fried, Linda F.
    Robbins, John
    Chaves, Paolo
    Cushman, Mary
    BLOOD, 2008, 112 (11) : 1183 - 1183
  • [37] Inflammation as a cardiovascular risk factor
    Willerson, JT
    Ridker, PM
    CIRCULATION, 2004, 109 (21) : 2 - 10
  • [38] Chronic inflammation and cardiovascular risk
    Ker, J. A.
    SOUTH AFRICAN FAMILY PRACTICE, 2010, 52 (01) : 18 - 18
  • [39] Obesity, Inflammation, and Cardiovascular Risk
    Mathieu, P.
    Lemieux, I.
    Despres, J-P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (04) : 407 - 416
  • [40] Inflammation, infection, and cardiovascular risk
    Drozd, Michael
    Cubbon, Richard
    LANCET, 2024, 403 (10431): : 1022 - 1023